WASHINGTON, Jan. 24 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company focused on developing and commercializing novel treatments for chronic diseases of the central nervous system, today announced that Dr. Kathleen Clarence-Smith has resigned from the Company as Chief Research and Development Officer and Director.
Dr. Clarence-Smith was a founder of Prestwick and previously served as its Chief Executive Officer and a member of its board of directors. Dr. Clarence- Smith's service as a member of Prestwick's board of directors ended on November 10, 2006. In a resignation letter to the Company, Dr. Clarence-Smith stated that she has resigned from her various positions with the Company to pursue other interests.
About Prestwick
Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.
Please go to www.prestwickpharma.com for more information.
Prestwick Pharmaceuticals, Inc.CONTACT: Brian Reid of WeissComm Partners, +1-703-402-3626, for PrestwickPharmaceuticals, Inc.
Web site: http://www.prestwickpharma.com//
